[Key words]177Lu-labeled prostate-specific membrane antigen radioligand therapy; Prostate cancer; Clinical practice; Expertconsensus 前列腺癌是男性常见的恶性肿瘤之一,预计2022年总患病人数为157万[1]。2024年国家癌症中心发布的中国恶性...
[34]SCHER H I, MORRIS M J, STADLER W M, et al. Trial design and objectives for castration-resistant prostate cancer: updatedrecommendations from the prostate cancer clinical trials workinggroup 3[J]. J Clin Oncol, 2016, 34(12): 1402-1418. [35] RAHBAR K, BÖGEMAN M, YORDANOVA A, et...
This method leverages the success of PSMA-targeted PET imaging, enabling delivery of targeted radiopharmaceutical therapy; has demonstrated a clear benefit in large prospective clinical trials; and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. This ...
Within the last decade, prospective clinical trials have led to widespread adoption of PSMA RLT (1-3). Currently, PSMA RLT is generally used in the castration-resistant phase after disease progression on an androgen-receptor-pathway inhibitor and taxane chemotherapy. Despite [~177Lu]Lu-PSMA's ...
INTERPRETATION :These externally validated nomograms that are predictive of outcomes after 177 Lu-PSMA in patients with mCRPC might help in clinical trial design and individual clinical decision making, particularly at institutions where 177 Lu-PSMA is introduced as a novel therapeutic option. FUNDING ...
This trial is registered with ClinicalTrials.gov, NCT03392428, and is complete. Findings: 291 men were registered from Feb 6, 2018, to Sept 3, 2019; after study imaging, 200 were eligible and randomly assigned to treatment with [177Lu]Lu-PSMA-617 (n=99) or cabazitaxel (n=101). After...
Clinical outcomes of 177 lu-psma radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–62. Article CAS PubMed Google Scholar Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratna...
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18. Article Google Scholar Seifert R, Herrmann K, Kleesiek J, Schäfers M, Shah V, Xu Z, et al. Semi...
[7] reported that an RBE value of 5 could be considered as an initial value based on limited data and might need to be changed with increasing number of clinical trials. The currently utilized RBE value of 5 does not account for the individual characteristic alpha particle energy of different...
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3[J]. J Clin Oncol, 2016, 34(12): 1402−1418. DOI: 10.1200/JCO.2015.64.2702. [32] Yadav MP, Ballal S, Tripathi M, et al. 177Lu-DKFZ-...